2024
Translating p53-based therapies for cancer into the clinic. Peuget S, Zhou X, Selivanova G. Nat Rev Cancer. 2024 Mar;24(3):192-215. doi: 10.1038/s41568-023-00658-3. PMID: 38287107
2023
Strategies to Isolate Extracellular Vesicles from Gram-Negative and Gram-Positive Bacteria. Narciso AR, Aschtgen MS. Methods Mol Biol. 2023;2674:61-70. doi: 10.1007/978-1-0716-3243-7_4. PMID: 37258960
MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation. Peuget S, Selivanova G. Cancer Discov. 2023 May 4;13(5):1043-1045. doi: 10.1158/2159-8290.CD-23-0229. PMID: 37139722
2022
Enterobacteria impair host p53 tumor suppressor activity through mRNA destabilization. Aschtgen MS, Fragkoulis K, Sanz G, Normark S, Selivanova G, Henriques-Normark B, Peuget S. Oncogene. 2022 Apr;41(15):2173-2186. doi: 10.1038/s41388-022-02238-5. PMID: 35197571